Inhibikase Therapeutics, Inc. (IKT)
1.59
-0.04
(-2.45%)
USD |
NASDAQ |
Oct 23, 16:00
1.585
0.00 (0.00%)
After-Hours: 20:00
Inhibikase Therapeutics Enterprise Value : 50.91M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 50.91M |
| October 22, 2026 | 56.19M |
| October 21, 2026 | 60.16M |
| October 20, 2026 | 66.76M |
| October 19, 2026 | 58.17M |
| October 16, 2026 | 58.84M |
| October 15, 2026 | 82.60M |
| October 14, 2026 | 78.64M |
| October 13, 2026 | 73.36M |
| October 12, 2026 | 84.58M |
| October 09, 2026 | 101.09M |
| October 08, 2026 | 93.16M |
| October 07, 2026 | 97.12M |
| October 06, 2026 | 102.41M |
| October 05, 2026 | 105.05M |
| October 02, 2026 | 105.05M |
| October 01, 2026 | 95.80M |
| September 30, 2026 | 112.31M |
| September 29, 2026 | 107.69M |
| September 28, 2026 | 111.65M |
| September 25, 2026 | 112.97M |
| September 24, 2026 | 118.25M |
| September 23, 2026 | 124.85M |
| September 22, 2026 | 145.98M |
| September 21, 2026 | 131.45M |
| Date | Value |
|---|---|
| September 18, 2026 | 144.66M |
| September 17, 2026 | 144.66M |
| September 16, 2026 | 145.98M |
| September 15, 2026 | 145.98M |
| September 14, 2026 | 156.54M |
| September 11, 2026 | 149.94M |
| September 10, 2026 | 148.62M |
| September 09, 2026 | 159.18M |
| September 08, 2026 | 161.82M |
| September 04, 2026 | 171.06M |
| September 03, 2026 | 173.70M |
| September 02, 2026 | 171.06M |
| September 01, 2026 | 155.22M |
| August 31, 2026 | 145.98M |
| August 28, 2026 | 159.18M |
| August 27, 2026 | 167.10M |
| August 26, 2026 | 169.74M |
| August 25, 2026 | 171.06M |
| August 24, 2026 | 171.06M |
| August 21, 2026 | 156.54M |
| August 20, 2026 | 151.26M |
| August 19, 2026 | 164.46M |
| August 18, 2026 | 157.86M |
| August 17, 2026 | 156.54M |
| August 14, 2026 | 159.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.59M |
| Total Expenses (Quarterly) | 19.59M |
| EPS Diluted (Quarterly) | -0.1122 |
| Earnings Yield | -27.45% |
| Normalized Earnings Yield | -27.57 |